The emergence of targetable MEKanisms in sporadic lymphatic disorders

Michael T Dellinger¹ & Francis X McCormack²*

Sporadic lymphatic diseases are orphans among orphans in the medical community, a diverse collection of disorders at the intersection of cardiac, gastrointestinal, pulmonary, dermatologic, and oncologic disease that receives only passing attention in medical school and that no subspecialty in medicine fully embraces as its own. They often present in a confusing and illusive manner, with a fractured bone, expectoration of blood or a branching airway cast, a swollen limb or a collection of chylosous material; protean manifestations that can challenge even the most expert diagnostician. Yet many of these acquired disorders have been discovered to have a targetable genetic basis, and as the case report of Foster et al (2020) demonstrates, the sedulous clinician–patient dyad can be rewarded with an almost miraculous result when the molecular pathogenesis of the disease is pursued and an exquisitely targeted therapy is administered.

EMBO Mol Med (2020) 12: e12822
See also: JB Foster et al (October 2020)

Each day, the lymphatic system resorbs 1–2 liters of protein-rich fluid from the interstitium of vascularized tissues and returns it to the venous system via a one-way vascular tree that originates with blind-ended, single-cell thickness vessels that connect to larger conducting vessels and ultimately to the thoracic duct and subclavian vein (Tammela & Altalo, 2010; Fig 1A). Dietary fats resorbed by lacteals of the small intestine are discharged into the flow, which also serves as a conduit for leukocytes that are extravasated from the blood circulation and recovered by lymphatic capillaries to interact with networks of lymph nodes and ultimately returned to the bloodstream armed with vital targeting directives. Intrinsic contractile action of the lymphatic conducting vessels and muscular action in the extremities propels fluid caudad, with retrograde flow prevented by intravascular valves. The lung lymphatics are a parallel system with lymphatic flow that is primarily propelled by the bellows action of respiration and that drains into the thoracic duct.

Sporadic lymphatic diseases that interfere with this vascular system can result in disruption of fluid homeostasis, nutrition, and immune function (Fig 1B). These include lymphangioleiomyomatosis (LAM) (Henske & McCormack, 2012), yellow nail syndrome (YNS), and those collectively termed the complex lymphatic anomalies (CLAs), including generalized lymphatic anomaly (GLA), Gorham–Stout disease (GSD), central conducting lymphatic anomaly (CCLA), and kaposiform lymphangiomatosis (KLA) (Trenor & Chaudry, 2014). Patients with these diseases can have tortuous dilated lymphatics, diffuse multifocal lymphatic malformations, dilated lacteals with protein-losing enteropathy, and ectopic lymphatics in bone and osteolytic lesions (Trenor & Chaudry, 2014). Lymphedema, pleural effusions, and ascites occur when antegrade lymphatic flow is obstructed or impeded by extrinsic compression from lymphatic masses, intraluminal obstruction, dysplastic transformation, or valvular destruction. Patients with disease above the level of the cisterna chyli can also present with chylosous fluid accumulations, leakages or discharges, protein-losing enteropathy or plastic bronchitis that results from reflux of lymphatic fluids containing chylomicrons into the pulmonary lymphatics, potential spaces, hollow viscerota, airways, or fistulous tracks. Recent advances in lymphatic imaging including T2-weighted MRI and MR lymphangiography have largely replaced lymphoscintigraphy and can reveal ectopic or dysplastic lymphatic masses, lymphatic leaks, and sites of lymphatic obstruction (Itkin & McCormack, 2016). Although new approaches to thoracic duct cannulation and embolization can be curative for refractory chylosous effusions, plastic bronchitis, and chylosous ascites, these techniques do not impact underlying disease pathogenesis or the effect of lymphatic disease on fluid homeostasis, pulmonary function, or osseous integrity.

Somatic mutations in TSC2 (Henske & McCormack, 2012), PIK3CA (Rodriguez-Laguna et al, 2019), ARAF (Li et al, 2019), and NRAS (Barclay et al, 2019) have been found in LAM, GLA, CCLA, and KLA patients, respectively (Fig 1B). Interestingly, these same mutations occur in cancer and cause either inappropriate PI3K/AKT/mTOR or MAPK signaling (Trenor & Chaudry, 2014). Sirolimus and everolimus are mTOR inhibitors that act downstream of most lymphatic disease driving mutations in the PI3K/AKT/mTOR pathway and have been proven to be remarkably effective at stabilizing or reversing disease manifestations in some patients with LAM, GLA, CCLA, and KLA (McCormack et al, 2011; Adams et al, 2016). However, not all adult lymphatic disease patients improve with sirolimus/everolimus (Adams et al, 2016) and it is clear we have much more to learn about the genetic basis and dysregulated signaling underlying these disorders.

¹Division of Surgical Oncology, Department of Surgery and the Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX, USA
²Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
*Corresponding author: E-mail: Frank.McCormack@uc.edu

DOI 10.15252/emmm.202012822 | EMBO Mol Med (2020) 12: e12822 | Published online 18 September 2020

© 2020 The Authors. Published under the terms of the CC BY 4.0 license
In this issue of *EMBO Molecular Medicine*, Foster et al (2020) describe a novel mutation and treatment for kaposiform lymphangiomatosis (KLA) in a patient with pericardial and pleural effusions, and who also had involvement of her mediastinum, lungs, right breast, axilla, spleen, and several bones. Although her disease had remained stable for many years on sirolimus, it worsened after discontinuing the drug and became unresponsive to sirolimus on a subsequent trial. Genetic analysis of endothelial cells isolated from her pleural fluid revealed that she had a somatic loss-of-function mutation in *CBL* (c.2322T>G; p.Y774*)*, a E3 ubiquitin–protein ligase that negatively regulates the RAS/MAPK pathway. Because the patient’s mutation was predicted to increase RAS/MAPK signaling, she was treated with trametinib, an FDA-approved MEK inhibitor. The patient’s disease rapidly improved following treatment and she experienced a near-complete resolution of her symptoms. Interestingly, lymphatic imaging revealed a remarkable “remodeling” of the drainage pattern of her lymphatic system after treatment.

The exciting findings by Foster et al (2020) shed new light on the pathogenesis of KLA, including insights into the genetics and pharmacotherapeutic approaches to the disease. Many unanswered questions still exist, including the mechanism by which CBL regulates RAS/MAPK signaling in lymphatic endothelial cells and leads to destructive remodeling, and whether there are differences in phenotype, prognosis, circulating angiopoietin-2 levels [a diagnostic biomarker for KLA (Le Cras et al, 2017)], or response to treatments between KLA patients with a CBL or NRAS mutation. What is clear is that supportive care alone is no longer the standard of care for patients with lymphatic disease. Clinicians who encounter these diseases are well advised to search for the genetic basis and deliver targeted therapies when available or refer to a specialized center with the expertise and resources to pursue a molecular diagnosis.

In conclusion, the paper by Foster et al (2020) offers new hope for patients suffering from KLA and all lymphatic disorders. Importantly, next-generation sequencing studies like the one described in this issue of *EMBO Molecular Medicine* could lead to the repurposing of additional FDA-approved pharmacotherapies for KLA and other CLAs and usher in a new era of precision medicine for the treatment of these life-threatening diseases.

**References**

Adams DM, Trenor CC III, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C et al (2016) Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. *Pediatrics* 137: 1–10

Barclay SF, Inman KW, Luks VL, McIntyre JB, Al-Ibraheemi A, Church AJ, Perez-Atayde AR, Mangray S, Jeng M, Kreimer SR et al (2019) A somatic activating NRAS variant associated with kaposiform lymphangiomatosis. *Genet Med* 21: 1517–1524

© 2020 The Authors

Figure 1. Lymphatic anatomy, genetic basis of sporadic lymphatic disorders, and targetable downstream signaling nodes.
(A) The lymphatic channels from the lower extremities, intestines, and liver converge on the cisterna chyli and drain into the subclavian vein via the thoracic duct. Genetic mutations that cause dysplasia or obstruction of lymphatic vessels can result in chylous ascites, chylothorax, chyluria, protein-losing enteropathy, or plastic bronchitis. Embolization via the thoracic duct can be attempted for downstream leaks, but is more difficult when addressing leaks from countercurrent, feeding circuits and tributaries that arise from the liver and mesentery. (B) Gain-of-function and loss-of-function mutations in the PI3K/Akt/mTOR and MAPK pathways can lead to sporadic lymphatic disorders, many of which are amenable to targeted therapies approved for other indications, such as sirolimus and trametinib. CCLA, central conducting lymphatic anomaly; GLA, generalized lymphatic anomaly; KLA, kaposiform lymphangiomatosis; LAM, lymphangioleiomyomatosis.
Foster J, Li D, March M, Sheppard S, Adams D, Hakonarson H, Don Y (2020) Kaposiform lymphangiomatosis effectively treated with MEK inhibition. *EMBO Mol Med* 12: e12324

Henske EP, McCormack FX (2012) Lymphangioleiomyomatosis – a wolf in sheep’s clothing. *J Clin Invest* 122: 3807–3816

Itkin M, McCormack FX (2016) Nonmalignant adult thoracic lymphatic disorders. *Clin Chest Med* 37: 409–420

Le Cras TD, Mobberley-Schuman PS, Broering M, Fei L, Trenor CC III, Adams DM (2017) Angiopoietins as serum biomarkers for lymphatic anomalies. *Angiogenesis* 20: 163–173

Li D, March ME, Gutierrez-Uzquiza A, Kao C, Seiler C, Pinto E, Matsuoka LS, Battig MR, Bhoj EJ, Wenger TL et al (2019) ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. *Nat Med* 25: 1116–1122

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med* 364: 1595–606

Rodriguez-Laguna I, Agra N, Ibanez K, Oliva-Molina C, Gordo G, Khurana N, Hominick D, Beato M, Colmenero I, Herranz G et al (2019) Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly. *J Exp Med* 216: 407–418

Tammela T, Alitalo K (2010) Lymphangiogenesis: molecular mechanisms and future promise. *Cell* 140: 460–476

Trenor CC III, Chaudry G (2014) Complex lymphatic anomalies. *Semin Pediatr Surg* 23: 186–190

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.